Search

Gilead is getting closer to a deal to buy Immunomedics for more than $20 billion - CNBC

A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018.
Stephen Lam | Reuters

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Journal said, citing people familiar with the matter.

Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation, the Journal added.

Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment.

Shares of Immunomedics, which last month reported positive data from a late-stage confirmatory study for Trodelvy, have nearly doubled this year, giving the company a valuation of close to $10 billion.

An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio.

It bought a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.

Let's block ads! (Why?)



Business - Latest - Google News
September 13, 2020 at 05:22AM
https://ift.tt/3bQYt9Y

Gilead is getting closer to a deal to buy Immunomedics for more than $20 billion - CNBC
Business - Latest - Google News
https://ift.tt/2Rx7A4Y


Bagikan Berita Ini

0 Response to "Gilead is getting closer to a deal to buy Immunomedics for more than $20 billion - CNBC"

Post a Comment

Powered by Blogger.